Abstract
Post-transplant lymphoproliferative disorder (PTLD) is a major contributor to post-transplant morbidity and mortality in pediatric heart transplant recipients. EBV viremia is associated with the development of PTLD in this population. We sought to evaluate the safety and efficacy of rituximab for the prophylactic treatment of refractory EBV viremia and prevention of PTLD in pediatric heart transplant recipients.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
Paper Title
Journal
Date
